Nerandomilast
Brand names: Jascayd · Active ingredient: Nerandomilast
In short: JASCAYD is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients. JASCAYD is indicated for the treatment of progressive pulmonary fibrosis (PPF) in adult patients.
What is Nerandomilast used for?
JASCAYD is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients.
JASCAYD is indicated for the treatment of progressive pulmonary fibrosis (PPF) in adult patients.
Nerandomilast dosage
The recommended dosage of JASCAYD is 18 mg twice daily, administered orally (swallow tablets whole or dispersed in water) approximately 12 hours apart, with or without food.
Reduce JASCAYD to 9 mg twice daily for patients who are unable to tolerate 18 mg twice daily, except in patients who concomitantly use JASCAYD with moderate CYP3A inducers or pirfenidone .
Recommended Dosage for Concomitant Use with Moderate CYP3A Inducers or Pirfenidone
Recommended dosage of JASCAYD is 18 mg twice daily when used concomitantly with moderate CYP3A inducers or pirfenidone. Do not reduce dosage to 9 mg twice daily .
Administration Instructions
Swallow JASCAYD tablets whole or dispersed in water .
Missed Dose(s)
If a dose of JASCAYD is missed, advise the patient to take the next dose at the next scheduled time. Advise the patient to not make up for a missed dose.
Maximum Recommended Dosage
The maximum recommended dosage of JASCAYD is 18 mg twice daily.
Strong CYP3A Inhibitors
Reduce JASCAYD dosage to 9 mg twice daily when used concomitantly with strong CYP3A inhibitors .
Moderate and Weak CYP3A Inhibitors
No dosage modification is recommended for JASCAYD when used concomitantly with moderate or weak CYP3A inhibitors.
Disperse JASCAYD tablet in water and administer as follows:
Place approximately 100 mL (3 to 4 ounces) of non-carbonated, room temperature water in a glass. Do not use any other liquids.
Place a JASCAYD tablet in the water, without crushing, and stir regularly for approximately 15 to 20 minutes until the tablet is dispersed into very small pieces (the tablet will not completely dissolve).
Drink the dispersion within 2 hours of mixing.
If the dispersion is not drunk immediately, stir again before drinking.
Rinse the glass with approximately 100 mL (3 to 4 ounces) of water and drink to ensure the full dose is administered.
How to take Nerandomilast — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Pregnancy
Advise female patients to contact their healthcare provider if they become pregnant or suspect they may be pregnant during treatment with JASCAYD. Advise female patients of the potential risk of fetal loss .
Missed Dose
Inform patients that if they miss a dose of JASCAYD, they should take the next dose at the next scheduled time. Advise patients to not make up for a missed dose or exceed the recommended dosage of 18 mg twice daily .
Warnings & precautions
Do not take this medicine if: None.
Nerandomilast side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions for Idiopathic Pulmonary Fibrosis
The safety of JASCAYD was based on a randomized, placebo-controlled, double-blind trial (FIBRONEER-IPF), which included 1,177 adult patients with IPF who were randomized in a 1:1:1 ratio to receive JASCAYD 9 mg twice daily, JASCAYD 18 mg twice daily, or matching placebo. Patients received JASCAYD or placebo with or without background antifibrotic treatment (nintedanib or pirfenidone) for at least 52 weeks . The median duration of exposure was 14 months in each treatment arm.
Discontinuation due to adverse reactions occurred more frequently in patients treated with JASCAYD (with or without background antifibrotic treatment) 18 mg (15%) and 9 mg (12%) compared to placebo (11%). The most frequent adverse reaction leading to discontinuation of JASCAYD 18 mg and 9 mg was diarrhea (6% and 2%, respectively).
Table 1 lists the most common adverse reactions from the studied population with an incidence of greater than or equal to 5% in JASCAYD-treated patients and more common than the placebo group. …
Drug interactions
Strong CYP3A Inhibitors
Reduce the dosage of JASCAYD to 9 mg twice daily when used concomitantly with strong CYP3A inhibitors .
Nerandomilast is a CYP3A substrate. Concomitant use of JASCAYD with a strong CYP3A inhibitor increases exposure of nerandomilast, which may increase the risk of JASCAYD adverse reactions .
Strong or Moderate CYP3A Inducers
Avoid concomitant use of strong CYP3A inducers with JASCAYD.
Recommended dosage of JASCAYD is 18 mg twice daily when used concomitantly with moderate CYP3A inducers. Do not reduce the dosage to 9 mg twice daily .
Nerandomilast is a CYP3A substrate. Concomitant use of JASCAYD with strong or moderate CYP3A inducers decreases exposure of nerandomilast, which may decrease the efficacy of JASCAYD .
Pirfenidone
Recommended dosage of JASCAYD is 18 mg twice daily when used concomitantly with pirfenidone. Do not reduce the dosage to 9 mg twice daily .
Concomitant use of JASCAYD with pirfenidone decreases exposure of nerandomilast . When JASCAYD was used concomitantly with pirfenidone in patients with IPF in FIBRONEER-IPF, efficacy was not observed with the JASCAYD 9 mg twice daily dosage .
About this medicine
JASCAYD (nerandomilast tablets), for oral administration, contain nerandomilast, a phosphodiesterase 4 (PDE4) inhibitor. The chemical name of nerandomilast is [1-[[(5R)-2-[4-(5-chloropyrimidin-2-yl)-1-piperidyl]-5-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl]amino]cyclobutyl]methanol. Nerandomilast has one chiral center and is the R-stereoisomer. Its structural formula is:
Nerandomilast is a white to off-white to light yellow powder with an empirical formula of C20H25ClN6O2S and a molecular weight of 449 g/mol. At or below pH 3, nerandomilast is very slightly to slightly soluble in water, and above pH 3 it is practically insoluble.
Each film-coated tablet of JASCAYD contains 9 mg or 18 mg of nerandomilast and the following inactive ingredients: croscarmellose sodium, ferric oxide red (18 mg tablets only), ferric oxide yellow (9 mg tablets only), ferrosoferric oxide (18 mg tablets only), hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, and talc. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fa1b14c6-957f-d326-5099-911bfe33e391. Read the full official label on DailyMed.